



## (51) International Patent Classification:

A61K 31/426 (2006.01) A61K 31/165 (2006.01)

## (21) International Application Number:

PCT/US2014/040286

## (22) International Filing Date:

30 May 2014 (30.05.2014)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

|            |                           |    |
|------------|---------------------------|----|
| 61/829,759 | 31 May 2013 (31.05.2013)  | US |
| 61/839,609 | 26 June 2013 (26.06.2013) | US |

(71) Applicants: **TAKEDA PHARMACEUTICALS U.S.A., INC.** [US/US]; One Takeda Parkway, Deerfield, Illinois 60015 (US). **TEIJIN PHARMA LIMITED** [JP/JP]; 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-0013 (JP).

(72) Inventors: **GUNAWARDHANA, Lhanoo**; 10143 48th Avenue, Pleasant Prairie, Wisconsin 53158 (US). **GUPTE, Vijay**; 1876 Olympic Drive, Vernon Hills, Illinois 60061 (US). **NAIK, Himanshu**; 1675 Church Street, Evanston, Illinois 60201 (US). **MAYER, Michael**; 1101 Edgewater Lane, Antioch, Illinois 60002 (US). **KOMATSU, Kanji**; # 6-F, Dai 23 Miyaniwa Manshon, 2-2-2 Okubo, Shinjuku-ku, Tokyo 169-0072 (JP).

(74) Agent: **SHANER, Sandra L.**; Cantor Colburn, LLP, 20 Church St., 22nd Floor, Hartford, Connecticut 06103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


## Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

## Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: METHODS OF TREATMENT AND COMPOSITIONS WITH XANTHINE OXIDASE INHIBITORS



(57) Abstract: Methods and pharmaceutical compositions for reducing number of gout flares experienced by a patient are disclosed. The methods can comprise administering to a patient with hyperuricemia an effective amount of a xanthine oxidase inhibitor in a modified release dosage form once daily or in an immediate release dosage form two or more times daily to prevent at least one gout flare or reduce the number of gout flares experienced by the patient.